Ruxolitinib and oHSV combination therapy increases CD4 T cell activity and germinal center B cell populations in murine sarcoma
Malignant peripheral nerve sheath tumors (MPNSTs) are a highly aggressive neoplasm of the peripheral nervous system and are resistant to most conventional cancer therapies. We previously showed that pretreatment with ruxolitinib (RUX) enhanced the efficacy of oncolytic herpes simplex virus (oHSV) vi...
Saved in:
Main Authors: | Ravi Dhital, Yeaseul Kim, Doyeon Kim, Ilse Hernandez-Aguirre, Jack Hedberg, Alexia Martin, Kevin A. Cassady |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2025-03-01
|
Series: | Molecular Therapy: Oncology |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2950329924001711 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE
by: Mi-Ae Lyu, et al.
Published: (2025-02-01) -
Editorial: Oncolytic virotherapy, volume II
by: Ahmed Majeed Al-Shammari, et al.
Published: (2025-01-01) -
Untreated HSV Leading to Neonatal Death
by: Meghan Sawyer, et al.
Published: (2025-02-01) -
Non-Melanoma Skin Cancer Aggravation in Polycythemia Vera: Triggered by Ruxolitinib and Silenced With an IFN/Cemiplimab
by: Efterpi Zafiriou, et al.
Published: (2025-01-01) -
Anti-HSV-1 agents: an update
by: Wenwen Lv, et al.
Published: (2025-01-01)